U.S. Markets closed

Bristol-Myers completes acquisition of Amylin

Bristol-Myers Squibb (BMY) announced that yesterday it successfully completed the tender offer by Bristol-Myers Squibb Company through its wholly owned subsidiary, B&R Acquisition Company, for all of the outstanding shares of common stock of Amylin Pharmaceuticals (AMLN) at a purchase price of $31.00 per share. As of the expiration of the offer yesterday, 140,550,153 shares of common stock of Amylin were validly tendered and not withdrawn in the tender offer. Bristol-Myers Squibb intends to delist and de-register Amylin common stock as promptly as practicable following the effective time of the merger.